Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older - Candlesense
VALN Regulatory

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older

Saint Herblain (France), August 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years and older. This announcement adds to the adult marketing authorization already received in Canada1 and complements the adolescent label extension received in Europe in April 20252.

Related Questions

Could the expanded age indication and regulatory clearance lead to broader global roll‑outs or partnership opportunities that impact the stock price? How will the Canadian approval of IXCHIQ® affect Valneva's revenue forecasts and valuation? What is the competitive landscape for chikungunya vaccines in Canada and how might this approval influence market share dynamics?
Find similar articles on Candlesense globenewswire